webmd An FDA advisory panel unanimously gave a green light on Monday to the Alzheimer’s disease treatment donanemab for use during the early stages of the disease.

The move makes it likely that the FDA will fully approve this monoclonal antibody drug. Donanemab targets the buildup of plaques in the brain that are an indicator of the severe form of dementia.

Clinical trial results published last year suggested that the treatment could slow the progression of the disease by a matter of months. This was based on people’s performance on tests that measure abilities related to cognition and to daily living skills, such as driving and managing finances.